Since the number of patients seen in a pediatric oncology center is relatively small, it is difficult to perform single drug phase two studies, even on a national base. This also probably explains the lack of information on ifosfamide, despite the fact that it has now been used for more than 10 years in pediatrics. As long as chemotherapy plays such an important role in childhood cancer it remains of the utmost importance to determine the role of ifosfamide in the treatment of young cancer patients.